Latest Breaking News On - Marketable debt securities - Page 1 : comparemela.com

Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial Results Diluted EPS of $1.23; Non-GAAP Diluted EPS of $2.19 – Full Year 2020 Year-Over-Year: – Product Sales increased 10% to $24.4 billion, primarily due to Veklury – – Diluted EPS of $0.10; Non-GAAP Diluted EPS of $7.09 – – Returned $5.0 billion of cash to shareholders through dividends and share repurchases – Full Year 2021 Guidance: – Product Sales including Veklury of $23.7 billion to $25.1 billion – – Operating … – Diluted EPS of $1.23; Non-GAAP Diluted EPS of $2.19 – Full Year 2020 Year-Over-Year: – Diluted EPS of $0.10; Non-GAAP Diluted EPS of $7.09 – – Returned $5.0 billion of cash to shareholders through dividends and share repurchases – Full Year 2021 Guidance: – Operating expenses flat to low single-digit percentage decline – – Non-GAAP Diluted EPS of $6.75 to $7.45 –

United statesFoster cityJacquie rossSonoma biotherapeuticsLedipasvir sofosbuvirSofosbuvir velpatasvirComplera evipleraNovo nordiskVir biotechnology incGritstone oncology incArcus biosciences incGilead sciences incJanssen sciences irelandEuropean unionAltera corpRacial equity community impact fund